Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Fulvestrant in FALCON trial improves PFS in advanced breast cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.16
Views: 1736
Rating:

Dr Matthew Ellis - Washington University in St Louis, USA

Dr Ellis talks to ecancertv at ESMO 2016 about the finding that fulvestrant significantly increased progression-free survival in women with hormone-receptor-positive advanced breast cancer, and particularly those with less aggressive lower-volume disease.

Read the news story for more.

These results were also discussed by Prof John Roberston here.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation